Director: Anna Webb
After completing a PhD at the MRC Human Genetics Unit in Edinburgh, Anna undertook postdoctoral research at UCL before moving to scientific publishing (Acquisitions Editor then Senior Editor of a medical genomics journal). She also gained several years of conference and events experience before joining the Myrovlytis Trust.
Charity Officer: Jazzmin Huber
Following a degree in Cancer Biology and Immunology at the University of Bristol and a Medical degree at the University of Birmingham, Jazzmin worked as a Doctor for the NHS, before joining the Myrovlytis Trust as a Charity Officer in February 2021.
Charity Officer: Katie Nightingale
Katie completed her PhD at the Roslin Institute in Edinburgh before moving to the University of Cambridge to undertake her postdoctoral work. She joined the Myrovlytis Trust as a charity officer in May 2021.
Office Manager: Katie Honeywood
Katie has over 20 years’ experience within a variety of administrative roles and has developed extensive experience in office management. Katie completed her ILM Level 5 in April 2021, and is also a trained project facilitator. She joined the Myrovlytis Trust as office manager in June 2021.
Professor Eamonn Maher
MD FRCP FMedSci, Professor of Medical Genetics and Genomic Medicine at the University of Cambridge, UK. Professor Maher’s work focuses on human genetic disorders. Current research interests include inherited and non-inherited kidney cancers, such as VHL and BHD syndrome.
Dr Laura Schmidt
PhD, Principal Scientist at the National Cancer Institute, NIH, USA. Dr Schmidt’s research focuses on identifiying new genes involved in familial renal cancer. Dr Schmidt was part of the teams that cloned the VHL tumor suppressor gene, and that identified mutations in Folliculin, the gene mutated in BHD syndrome.
Professor Andrew Tee
PhD, Research Lecturer at the Institute of Medical Genetics of Cardiff University School of Medicine, UK and AICR fellow. Dr Tee leads a research group investigating the cellular mechanisms underlying tuberous sclerosis complex and BHD syndrome, particularly the activity of a key protein called mammalian target of rapamycin (mTOR).
Dr Dimitrios Iliopoulos
Dr. Dimitrios Iliopoulos is co-founder & Chairman of Attica Sciences Ltd, a biotech company developing innovative therapies for different cancer types, including osteosarcomas. He was a faculty at Harvard & UCLA Medical Schools and and Founder & Director of the UCLA Center for Systems Biomedicine funded by the Eli & Edythe Broad Foundation. He has received several national and international awards for the identification of novel genes and development of drugs for patients with cancer and autoimmune diseases.
Professor Daniel Gale
Daniel Gale is St Peter’s Chair of Nephrology at University College London. He leads a research group studying the genetic and biological mechanisms underlying renal diseases. He discovered, and identified the causes of, the diseases HIF2α erythrocytosis with pulmonary hypertension, which results from a defect of oxygen sensing, and CFHR5 nephropathy, which results from a defect of complement regulation and is endemic in Cyprus. Using large-scale genomics his group has also advanced understanding of the genetic architecture of disorders including IgA nephropathy, C3 glomerulopathy, and steroid sensitive nephrotic syndrome.
Professor Ann Nordgren
Ann Nordgren is Adjunct Professor of Clinical Genetics at Karolinska Institutet and Senior Consultant at the Department of Clinical genetics, Karolinska University Hospital. Her clinical work is mainly focused on genetic counceling, syndrome diagnostics and childhood cancer predisposition. Ann is group leader of the Rare Diseases Research group at KI and is responsible for a large national Childhood Cancer Predisposition (ChiCaP) initiative within Genomic Medicine Sweden. She is also leader of Karolinska Undiagnosed Diseases Program (K-UDP) a large clinical and research multidisciplinary expert team for syndrome diagnostics and member of the Undiagnosed Diseases Network International (UDNI).
Professor Manuel Ramirez
Manuel Ramirez is Head of the Advanced Therapy Unit at Hospital Universitario Niño Jesús, Madrid. He is responsible for the Oncohematology Diagnostics Unit, and of the Oncohematology Research laboratory. His research has a clear translational focus on advanced therapies for paediatric diseases, mostly hematology and oncology. His work is enabled by the fully validated GMP facility for manufacturing cell- and gene-therapy medicines, and engineered tissue medicines, the only of its type in a paediatric hospital in Spain. Manuel’s work encompasses all steps of the translational cycle, from preclinical (experimental lab and animal models) to clinical (clinical trials and compassionate use programs).
Professor Alejandro Sweet-Cordero
Alejandro Sweet-Cordero is a cancer biologist and practicing pediatric oncologist focused on basic and translational cancer research. His laboratory’s disease focus includes pediatric sarcomas and lung cancer. Their sarcoma work is focused on defining mechanisms driving osteosarcoma and Ewing sarcoma progression, metastasis and therapy resistance. He has extensive expertise in integrative genomic analysis (WGS, RNAseq, ATACseq) and functional genomic studies using CRISPR/CAS9. He uses these tools to drive gene and network discovery using primary tumors, patient-derived xenograft models, and genetically engineered mouse models. Alejandro also has experience in real-world application of tumor sequencing for precision cancer medicine and currently leads the Molecular Oncology Initiative (MOI) at UCSF.
Professor William Newman
William Newman is a consultant Clinical Geneticist in Manchester and the Clinical Director of the NW Genomic Medicine Service Alliance (GMSA). He also Chairs the NHSE Clinical Genomics Clinical Reference Group for Clinical Genomics. William has a long-standing interest in the discovery of genes resulting in rare inherited conditions, especially related to Perrault syndrome (hearing loss and ovarian failure) and bladder disorders. This work has resulted in a greater understanding of the causes of these conditions and is now progressing to develop therapeutic approaches.
Dr Logan G. Spector
Logan G. Spector received his Ph.D. in Epidemiology in 2002 from Emory University. After a year as a National Cancer Institute-funded postdoctoral fellow at the University of Minnesota, he joined the faculty as Assistant Professor of Pediatrics in the Division of Epidemiology/ Clinical Research at the University of Minnesota. His research focuses on the causes of childhood cancer with a focus on childhood leukemia, bone sarcomas, and hepatoblastoma. His work includes both traditional and genetic epidemiologic approaches. He is currently Chair of CLIC, which pools epidemiologic studies of pediatric cancers from across the world to better ascertain their causes.
Dr Tian Zhang
Tian Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School and completed post-graduate training at Duke University. She is currently Associate Professor within the Division of Medical Oncology and Department of Medicine at Duke, specializing in genitourinary (GU) malignancies. She actively leads both clinical and translational research studies in the GU Oncology, Phase 1, and Center for Cancer Immunotherapy groups. She is the overall study chair for the phase 3 PDIGREE trial for metastatic renal cell carcinoma in the National Clinical Trials Network and also serves as PI for several investigator-initiated trials. Her research focus is in improving novel therapies and biomarkers for patients with prostate, kidney, and urothelial cancers.
Robin Jones is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle. His main research interest focuses on clinical trials and translational research in sarcomas.
Becoming a Trustee
The Myrovyltis Trust promotes research into rare genetic disorders such as Birt-Hogg-Dubé syndrome and rare cancers such as Osteosarcoma. We have funded more than £6 million in research grants to laboratories around the world.
We are in a period of reinvigorating the charity, with a new business plan in place along with a new staff team who are committed to the direction the charity is taking.
We are seeking to appoint both a Vice Chair and new Trustees who have the experience to promote the charity’s vision, mission and goals, and assist with strategy development to ensure the charity meets its financial, legal and governance obligations.
Candidates should be aligned to the ethos of the charity and be keen to contribute their expertise to provide governance and support. We would love to hear from people with a variety of backgrounds to help us develop a diverse board. A scientific or medical background is not essential. We are particularly interested to hear from individuals with skills in finance, strategy, fundraising, scientific research or governance, as well as those with lived experience of a rare disease
This is an exciting time to be joining a small but agile charity with big plans to expand their remit in the world of rare diseases.
To apply please send a copy of your CV and covering letter to firstname.lastname@example.org
For an informal discussion on the roles please email Anna Webb, Charity Director, at email@example.com
We have created a Trustee Handbook to assist both current and prospective Trustees.
This handbook sets out the purpose, responsibilities and roles expected of all Myrovlytis Trust Trustees. It has been designed to provide you with an understanding of how we operate as an organisation and what is expected from you in your role as a trustee.
We value our trustees and are grateful for the continued support and commitment they bring to the Myrovlytis Trust.